infliximab
janssen,Celltrion
['infliximab']
prof s hanauer presents results of sc infliximab biosimilar ct-p13 for cd (liberty) both co primary endpoints at wk 54 (clinical remission and endoscopic response) were met, as well as key 2* endpoints pk also quite favorable #ddw2023 
I'm a Mayo specialist in evaluation and management of patients with ulcerative colitis and Crohn's disease. Tweets are mine. Retweet doesn't mean endorsement.